Winer et al. treated a 64-year-old patient with Lynch syndrome associated mCRC and urothelial carcinoma with the anti-PD-L1 antibody atezolizumab after progression on pembrolizumab and subsequently with ipilimumab and nivolumab after clinical progression marked by rising tumor markers. The gene discussed is CD274; the disease is neoplasm.